TCGA-FD-A5BV-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.354796321
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.310
- PANCREAS_BETA_CELLS+0.250
- APICAL_SURFACE+0.230
- SPERMATOGENESIS+0.220
- KRAS_SIGNALING_DN+0.200
- ESTROGEN_RESPONSE_LATE+0.170
- KRAS_SIGNALING_UP+0.120
- COAGULATION+0.110
- ESTROGEN_RESPONSE_EARLY+0.110
- E2F_TARGETS+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- OXIDATIVE_PHOSPHORYLATION-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.380
- MITOTIC_SPINDLE-0.350
- P53_PATHWAY-0.350
- MYC_TARGETS_V1-0.320
- PI3K_AKT_MTOR_SIGNALING-0.310
- TGF_BETA_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG225 | — | — | 0.849 |
| 2 | TCGA-DK-A3X1-01A-12R-A22U-07 | — | — | 0.835 |
| 3 | SRR12202428 | — | — | 0.833 |
| 4 | SRR1442195 | GTEX | — | 0.832 |
| 5 | MNG1143 | — | — | 0.824 |
| 6 | MNG35 | — | — | 0.822 |
| 7 | SRR12696783 | — | — | 0.821 |
| 8 | MNG584 | — | — | 0.819 |
| 9 | MNG189 | — | — | 0.819 |
| 10 | SRR1475386 | GTEX | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |